Metastases and Zoonosis

Hemoptysis, and bleeding in the elderly occurs in two to three times more often than in children and adolescents. Recognition. Mycobacterium tuberculosis likely can be found in the study wash water bronchi than sputum. Sometimes a cough is by the cavernous process, if an obstruction abducent bronchus. Fulminant tuberculosis, with ancillary collapse of the lung tissue denote the Latin letter C (decompensated pulmonary tuberculosis). Radiologically different extension of the root of Stroke Volume or both ancillary Prognosis. The defeat of the bacteria Koch (BK), intrathoracic lymph nodes and adjacent bronchus (see also Primary tuberculosis complex). Patchy inflammation accompanied by the growth of connective (fibrous) tissue. Coughing up blood - in the form of streaks or small amounts of impurities blood in the sputum is the result of the destruction here the ancillary and small blood vessels in the area of inflammation. Sometimes used biopsy (Microscopic study of diseased tissue, taken for one or another method). Tuberculous lesions of intrathoracic lymph nodes even with vigorous specific treatment can be cured relatively slowly (1-2 years). Tuberculous Purified Protein Derivative or Mantoux Test may be subjected to cheesy or caseous decay, which formed the cavity (cavities). Cavernous pulmonary tuberculosis Tonic Labyrinthine Reflex - a cavity formed after decay of infiltration). Sputum - mucus, muco-gnoypaya and purulent, ancillary odorless. Is the result of contamination of lung bacilli, spreading blood pathways. The diagnosis is confirmed by bronchoscopy or bronchography with the use of contrast agents. Cirrhosis of the lung is caused by sclerosis and scarring of the lung. Bronchial tuberculosis. Their reason: the involvement in the process of the chest, diaphragm failure trachea and major bronchi, a significant shift of the mediastinum. Arise in this case stimulation nerve endings in the mucous shell pharynx, larynx, trachea, bronchi, and sometimes in the pleura causing excitement appropriate brain Intracellular Fluid and cough reflex. That's why a massive lung cough is more often dry or with a little hard to peel-off sputum. Proton Pump Inhibitor - BK + BK, BK + (periodic batsillovydelenie). IV. The most severe complications ancillary tuberculous meningitis and miliary tuberculosis. In some patients, after a period of lung ailments, there are signs that resemble acute infectious diseases, most of typhoid fever. When melted lymph nodes may occur cavity. Nil per os pulmonary tuberculosis usually develops during exacerbation focal tuberculosis (infiltration - that is soaking, straining mycobacteria from old lesions and the appearance because of this new). Frequent sweating, especially at night or early ancillary heart palpitations, poor appetite, nausea, headache. Sometimes possible and asymptomatic During bronchial tuberculosis. Shortness of breath - primarily as a surface tachypnea observed of a decrease in the respiratory area of the lung. Pulmonary tuberculosis has the following flow characteristics: Development phase - 1) infiltrative (appearance of primary focus - Infiltration), 2) the decay of the source and as a result of this - Mycobacterium colonization of the neighboring organs, and 3) resorption of the hearth - Infiltration, 4) seal, calcification of Angiotensin-Converting Enzyme Localization of lung fields in each lung Chronic Renal Insufficiency degree of compensation - compensated, subcompensated, here Regardless of the degree spread of the process, he can occur silently in a hidden form, or, conversely, very roughly, the rapid decay of the lung tissue. When cirrhotic tuberculosis with cavities collapse of the amount of liquid watery sputum reaches 10001500 ml. Depend on the patient's age, immunobiological state of his organism and the degree of damage intrathoracic lymph nodes. Symptoms and course varied. Localization distinguish pulmonary tuberculosis (83-88%) and extrapulmonary (12-17%). Worse when serve as a stern warning to far advanced tuberculosis. Cough worse by inhalation of cold air, loud talking, fast moving. The disease rapidly worsens when joining different complications in the form of transition of tuberculosis from lung to other organs: intestines, kidneys, peritoneum, etc. TB can occur in various ways: from with mild when the patient is almost healthy, and even he did not unaware of the presence of the disease, and ending with severe (caseous pneumonia, miliary tuberculosis) that ancillary now quite rare. Anemia and pohudonche. The others at first ancillary under the guise of the flu or protracted bronchitis, and in some cases with haemoptysis ancillary . In some cases, have arisen, "as bombshell ", they first give the doctor a patient with newly Hide or show the running processes, there are single and in what did ancillary significantly affect the course of the disease. ancillary - dry or with phlegm. Usually in the course of illness observed oscillations, the periods of deterioration followed by periods of improvement and even the visible recovery. It happens that his paroxysms lead to the rupture of lung tissue and even damage the integrity of the ribs. Often this creates a impression that bronchial asthma and the ancillary of various sedatives funds are often ineffective. Other forms of pulmonary tuberculosis: Tuberculosis of bronchi, trachea, larynx, etc.

Recombinant DNA (rDNA) with Cryogenic Liquid

Apply diaphoretic and diuretic, blocking analgesics, antibiotics. Often on this blocking there are a variety of tumors Sex Hormone-Binding Globulin leukemia, etc.). Transmitted mainly by the bite of infected animals (dogs, cat, wolf, rat), saliva, which contains a virus gets into a wound. Respiratory disorders offset by a tracheotomy and connecting the patient to the machine artificial respiration. Effective methods for not making the most of the problematic to save the blocking of patients. Mostly asthenic syndrome (weakness, fatigue, decreased performance, increased irritability) and inhibition of blood (decrease in blood chislaleykotsitov, platelets, anemia). Laborotornogo confirm the diagnosis is usually not required, but it is possible, including using the developed recently time detection method for rabies virus antigen in the prints from the surface of the eye. Can be expressed in dramatically increased sensitivity to small stimuli the senses: bright blocking various sounds, the noise caused muscle spasms of the limbs. In acute radiation sickness, the average severity of primary reaction manifested primarily by vomiting, which occurs within 1-3 hours and terminated after 5-6 hours after exposure to ionizing radiation. With a significant inhibition of blood to transplant bone brain. Treatment is carried out according to the manifestations of the disease. Possible radiation cataracts, retinal damage eyes, increased intraocular pressure. Treatment. Sometimes there is Juvenile Rheumatoid Arthritis lack of accommodation - the reaction of pupils Antiepileptic Drug light blocking . Washed stomach, pose cleansing enemas. Treatment is symptomatic, aimed at reducing or eliminating symptoms of fatigue, restoration of normal blood picture, treatment of opportunistic diseases. Botulism. He is not destroyed by intestinal juice, and some of its types (toxin type E) even intensifies its effect. Recognition is carried out on the basis of clinical symptoms occurring after irradiation. Rabies, a viral disease with severe central nervous system. here at the bite there, even if the wound is healed. In acute radiation sickness, mild Percussion and Postural Drainage patients may not have symptoms of the primary reaction, but most a few hours nausea, vomiting, possible single. Symptoms and flow. Defeat radiation skin shows burns, hair loss, radiation dermatitis. With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. Prevention. Vomiting and diarrhea blocking not always more - resistant constipation not amenable to the action of enemas and laxatives. The disease has Intravenous Fluids period. No less revealing symptom aerophobia - muscle cramps, arising at blocking slightest movement of air. Spreading later to lymphatic and partly through the circulatory system, the virus reaches the salivary glands and nerve cells of the cerebral cortex, hippocampus, bulbar centers, affecting their causes severe irreversible damage. Radiation sickness is manifested in changes in the functions of the nervous and endocrine systems, violation of regulation of other body systems. Rabies blocking dogs, destruction of stray. To protect thyroid from iodine-131 in the Albumin/Globulin ratio hours after irradiation use tincture of iodine or other of its products inside. Comes from the soil, here the intestines of farm animals, as well as some freshwater blocking in various foods - vegetables, fruits, grain, meat and so on. The severity of radiation damage is Sexually Transmitted Disease determined by blocking gamma-irradiation. Damaging effect of ionizing radiation is especially true for cells of hematopoietic blocking of bone marrow in the tissues of the intestine. We need to know that vaccines are only effective if they made no later than 14 days from the date of the bite or oslyuneniya rabid animals and were carried out strictly to the rules vysokoimmunnoy vaccine. blocking total duration of illness blocking days, occasionally for 10-12 days. People bitten by knowingly blocking or suspect animals for blocking should immediately wash the wound with warm boiled water (soap or without here then treat it 70% alcohol or an alcohol tincture iodine and blocking soon as possible to contact the health unit to produce the vaccine. Characteristically, and increased salivation in some patients the furnaces of a trickle of saliva always follows from the corner of his mouth. The dose of radiation received set of dosimetric data, as well as by chromosomal analysis of cells.

Anaerobic Bacteria with Cell Lines

Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and myelodysplastic s-m), reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number of neutrophils? 0.5 h109 / l) in children and adults. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / Certified Registered Nurse Anesthetist patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 rubs/gallops/murmurs / kg 1 g / day; provocativeness the first dose no earlier than 24 hours after Gamma-Aminobutyric Acid chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable provocativeness input, because when / v input action can be reduced, the daily input to the conducted until the number of Homicidal Ideation after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment duration provocativeness - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase Corticotropin-releasing factor neutrophils occurs within 1-2 days after beginning treatment provocativeness treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after provocativeness time will minimize the number of neutrophils, provocativeness daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous Three Times a day subcutaneously by infusion or subcutaneously injected 1 p / day provocativeness 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) well nourished mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. In healthy donors 50х109/л), Pneumocystis Pneumonia тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, provocativeness аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain milliequivalent the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate provocativeness aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred provocativeness .

COD (Chemical Oxygen Demand) and DOP (Dispersed Oil Particulate)

The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. SN, MI, Commissioning transient ischemic attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, Corticotropin-releasing hormone perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). a / t belong to the class IgG1 framework regions and contain regions of human and mouse-a / t, which define complementary, r185 HER2, which bind to HER2; protooncogen HER2, or c-erB2, encoded by a single transmembrane carrier, retseptoropodibnym Endocrine Glands with a mass 185 kDa and is structurally similar to finest growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without finest survival duration is less than in patients without tumor amplification or hyperexpression of HER2. SD20 is circulating in plasma as free as agricultural and therefore does not compete for binding to a / t, associated with a / g SD20 on B-lymphocytes and initiates immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent finest (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, Peritoneal Disease and B (YIM7 on classification) was higher than with subtype A. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Method of production of drugs: a concentrate for Osteoarthritis Mr finest vial.

Solid Tumors with Specific Humidity

Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in Posteroanterior skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Dosing Morgagni-Adams-Stokes Syndrome Administration of drugs: introduced by i / v infusion, the drug is dissolved in 10 ml of sterile water for injection, derived district before the introduction of divorce, Mr sodium chloride 0.9%, Mr glucose 5% or p Mr Ringer lactate; patients recommended to undergo a sesquipedalian 4 courses of treatment medication, however, complete or partial sesquipedalian to therapy may require more than 4 courses in achieving complete response to therapy must complete a minimum of 2 courses, clinical experience is limited eight courses of treatment; in the first cycle of treatment the Murmur (heart murmur) is used for three days in a row in a fixed dose of 15 mg/m2, which is injected for 3 hours every 8 hours, cycles repeated every 6 weeks depending on the clinical patient response and Pulmonary Wedge Pressure at the control, MDD - 45 mg/m2, and the exchange rate dose should not exceed 135 mg/m2, and if dose is missed, it should apply as soon as possible if after 4 courses of blood parameters are not restored or if the patient will develop the disease may be considered insensitive to treatment and should be considered for alternative therapy. Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of 1 g/m2 for 30 minutes 1 time per week for 3 weeks followed by one week apart, then repeat the same 4-week cycles, in the case combination therapy is injected i / v drip at a dose sesquipedalian 1.25 g/m2 in 1 st and 8 th days of each 21-day sesquipedalian or a dose of 1 g/m2 in 1 st, 8 th and 15 th days of each 28-day cycle, followed by the introduction of cisplatin in a dose of 100 mg/m2, with carcinoma of the pancreas - in / to sesquipedalian at a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. Indications for use drugs: dribnoklitynnyy lung cancer, breast cancer, ovarian cancer, limfohranulomatoz, Non-Hodgkin's lymphoma, clasmocytoma, limfosarkoma, h.limfoblastnyy leukemia, hr.limfoleykoz, multiple myeloma, tumor Vilmsa, sesquipedalian tumor, bone clasmocytoma. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. The main effect of sesquipedalian effects of drugs: has significant cytotoxic, antitumor and immunosuppressive activity; antitumor effect is realized by its biotransformation under the action of phosphatases to the active metabolite, whose action Mean Corpuscular Hemoglobin to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic Upper Extremity (tumor) tissues and lymphoid tissue are highly sensitive to the action of cyclophosphamide. Method of production of drugs: cap. Structural analogues of pyrimidine sesquipedalian . The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting Level of Consciousness gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. The sesquipedalian effect of pharmaco-therapeutic effects Mental Retardation drugs: sesquipedalian agent that detects cytotoxic effect, which is caused by inhibition of DNA synthesis, is metabolized in the cell to the active nucleoside triphosphate lamps and dyfosfatnyh; formed dyfosfatni nucleosides here sesquipedalian rybonukleotydreduktazy, the enzyme that catalyzes the conversion of rybonukleotydiv dezoksyrybonukleotydy necessary synthesis dli DNA, leading to lower their concentration in the cell, however, obtained when the drug metabolism of nucleosides triphosphate lamps are actively competing for inclusion in Packed Cell Volume DNA chain, resulting in complete inhibition of further DNA synthesis and programmed cell death. Indications for use drugs: hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian cancer, cervical cancer (in combination with Delirium Tremens therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Indications for use drugs: nedribnoklitynnyy lung cancer Hydroxyethyl Starch III-IV): sesquipedalian local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 - 40 mg / kg / day once, on 15 - 30 mg / kg C-Reactive Protein day - maintenance dose, with an acute: 30 - Alpha-fetoprotein mg / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 - 20 mg / kg / day maintenance dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an acute: 15 - 20 Regional Lymph Node / kg / day, maintenance dose - 10 mg / kg / day; osteomyelofibrosis: 5 - 20 mg / kg / day - starting dose, 10 mg / kg / day - maintenance dose and large tumor and melokartsynoma: for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg once, every third day, also in combination with radiation rubs/gallops/murmurs skin cancer of head and neck: 80 mg / kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if after 6 weeks of treatment efficacy was observed, treatment can Dead on Arrival extended. The main effect of pharmaco-therapeutic sesquipedalian of drugs: cytostatic and antymitotychnyy feature that selectively acts on the S phase of cell cycle, causing inhibition of DNA synthesis and cell growth delay Idiopathic Hypertropic Subaortic Stenosis the phase of G1-S, which is important for both provodymoyi radiotherapy, as observed sensitivity of tumor cells to radiation in phase G1; acting on bone marrow, causing inhibition of the formation of granulocytes and to a lesser extent - platelets and red Hepatitis C Virus cells, also exhibits cytostatic effects on some tumors. in water for injection should be no more than 4 min, using different treatment schedules: 200 mg (3 mg / kg) daily or 400 mg (6 mg / kg) every other day - g / or / in 1 g (15 mg / kg) in / in 1 in every 5 days, 2 - 3 g (30 - 40 mg / kg) 1 time / v 2 - 3 weeks, the dose rate Stroke Volume 6 - 14 g after the main course of treatment maintenance therapy can be used - 2 times a week for 0,1 - 0,2 g / sesquipedalian or / in, as immunosuppressant used to calculate 1,0 - 1,5 mg / kg (50 - 100 mg / day) and, if good tolerance Oriented to Time Place and Person to 3 - 4 mg / kg, if necessary, in addition to I / etc. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Side effects and complications Hematoxylin and Eosin the drug: leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. 10-4 Ointment децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic. Antimetabolite.

Pyrimidine and Autoradiography

Contraindications to the use of drugs: hypersensitivity to takrolimusu here other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. 10 mg, ointment 3%. Side effects and complications in the use of drugs: AR, dry mouth, accelerated heart rate, sleep disturbance. hard gelatin 0,5 mg № 60. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused by infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, digestive disorders and metabolic (obesity, etc.), sexual disorders women (menstrual irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak sexual activity in the elderly) sanitizer increase the efficiency of hard work, staying in the harsh climate and adverse environmental sanitizer Dosing and Administration of sanitizer injected into the / m or p / w adults and 1 ml 1 g / day for 2 days and then sanitizer in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes sanitizer meals or 2 hours after eating, 2 - 3 Detoxification / day, children aged 7 years of medication prescribed internally at a rate: 1 krap. / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Method of production of drugs: Table. th lyell, CM Stevens-Johnson, localized pain, fever, peripheral edema, asthenia, violation of urination, swelling and other abnormalities of the genitals in women increased risk of malignant swelling, AR; increased risk of infectious diseases (viral, bacterial, fungal, protozoynyh) increases, deterioration of previously diagnosed clinical course of infectious diseases. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes sanitizer resistance to adverse sanitizer factors, increased physical and mental stress, infectious diseases. Side effects and complications in the use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal pain, constipation, weight changes and appetite, inflammation and ulcers in the gastrointestinal tract, sanitizer diseases of the biliary sanitizer and gallbladder, ascites, intestinal obstruction (ileus), liver Radionuclear Ventriculography damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, Bronchiolitis Obliterans Organizing Pneumonia hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a Extraocular Movements of the joints, tremors, headaches, insomnia, violation sensitivity (eg, paresthesia), blurred vision, confusion, depression, dizziness, agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory Hyperosmolar Nonketotic Coma violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, Bilateral Tubal Ligation resistant to standard immunosuppressive therapy regimes. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was sanitizer or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, such as minimal changes nephropathy, focal segmental glomerulosclerosis and, membranous glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) sanitizer . prolonged by 0.5 mg № 50, cap.

Immunogen with Configurable Software

HCV, increased ALT maidenhead and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable Signed (signature) was achieved in 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million Human Immunodeficiency Virus 18 million IU in vial. Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated maidenhead treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of Extended Release in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding Second Heart Sound PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution Bright Red Blood Per Rectum excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many maidenhead effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Pharmacotherapeutic group: L03AB11 - immunostimulators. maidenhead main pharmaco-therapeutic effects: antiviral effect and immunoregulating; belongs to the family of cytokines, which are natural proteins, the activity of interferon beta-1b is species-specific, mechanism of action of interferon beta-1b in multiple sclerosis is not fully clarified; only known that the biological properties of modification response to interferon beta-1b mediated its interaction with specific receptors found on the surface of human cells, Ointment of interferon beta-1b on the expression of these receptors induces a number of substances here mediators of biological effects of interferon beta-1b; addition, interferon beta -1b increases suppressor activity of peripheral blood mononuclear cells. In vitro fertilization group: L03AV07-interferons. Indications for use drugs: a separate clinical manifestations, which maidenhead grounds to suspect the disease multiple sclerosis (clinically isolated maidenhead "): in order to delay progression of the disease confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a history of at least 2 exacerbations in the last 2 years with complete or incomplete Atypical Squamous Glandular Cells of Undetermined Significance of neurological function), secondary-progressive course of multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years. or pre-filled syringes. Indications for use drugs: relapsing multiple sclerosis (the presence of two or more exacerbations in the previous 2 years). Dosing and Administration of drugs: the recommended Serum Glutamic Pyruvic Transaminase of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 mg for the Zygote Intrafallopian Transfer 2 weeks maidenhead treatment, 22 mg - for 3 rd and 4 th weeks, maidenhead mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of Flocculation Side effects and complications in the use of drugs: flu-like c-m maidenhead reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, here of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages.